Journal of Clinical Endocrinology & Metabolism, Vol 45, 353-362, Copyright © 1977 by Endocrine Society

ARTICLES

A new and superior adrenal imaging agent, 131I-6beta-iodomethyl-19-nor- cholesterol (NP-59): evaluation in humans

SD Sarkar, EL Cohen, WH Beierwaltes, RD Ice, R Cooper and EN Gold

We have reported tissue distribution studies in rats and dogs with a new adrenal imaging agent. 131I-6beta-iodomethyl-19-nor-cholesterol (NP- 59). This agent concentrated five times higher in the adrenal cortex than 131I-19-iodocholesterol without increased concentration in non- adrenal tissues. We now report in 34 patients, the findings on scintigraphy with NP-59 compared with angiograms and/or adrenal vein hormone levels and histopathology, including 13 patients with hypercortisolism, 12 with primary aldosteronism, 2 with low renin hypertension, 5 with catecholamine excess, 1 with a liver metastasis from an aldosterone producing adrenal cortical carcinoma, and 1 with anaplastic adrenal cortical carcinoma. NP-59 adrenal cortical uptake was more rapid and intense and background activity was less prominent, allowing earlier and more definite interpretation of images than was possible with 131I-19-iodocholesterol.

This article has been cited by other articles:

				J. W. Funder, R. M. Carey, C. Fardella, C. E. Gomez-Sanchez, F. Mantero, M. Stowasser, W. F. Young Jr., and V. M. Montori Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3266 - 3281. [Abstract] [Full Text] [PDF]